Labgenomics Co

Labgenomics Co Net Change in Cash

The Net Change in Cash of Labgenomics Co (084650.KQ) as of Nov 5, 2026 is -17.75 B KRW. In the previous year, Net Change in Cash was -17.81 B KRW — a change of -0.37% (higher).

Net Change in Cash

-17.75 BKRW

YoY

-0.37%

Last updated:

Net Change in Cash of Labgenomics Co is 2025 -17.75 B KRW. Net Change in Cash of Labgenomics Co was 2024 -17.81 B KRW. It decreases by -0.37% higher compared to the previous year.

The Labgenomics Co Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2018
-96.30 M KRW
Jan 1, 2019
1.60 B KRW
Jan 1, 2020
35.84 B KRW
Jan 1, 2021
32.69 B KRW
Jan 1, 2022
27.98 B KRW
Jan 1, 2023
-56.19 B KRW
Jan 1, 2024
-17.81 B KRW
Jan 1, 2025
-17.75 B KRW
The Labgenomics Co Net Change in Cash history
YEARNet Change in CashYoY
-17.75 BKRW-0.37%
-17.81 BKRW-68.30%
-56.19 BKRW-300.79%
27.98 BKRW-14.41%
32.69 BKRW-8.77%
35.84 BKRW+2,143.07%
1.60 BKRW-1,759.15%
-96.30 MKRW-98.95%
-9.21 BKRW-210.11%
8.37 BKRW-313.60%
-3.92 BKRW-205.73%
3.70 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Labgenomics Co Stock analysis

What does Labgenomics Co do? LabGenomics Co., Ltd. generates revenue through the provision of in vitro diagnostic (IVD) products and services. The company offers general diagnostic check services, molecular diagnostic check services, and research and development services, alongside IVD products such as DNA chips and PCR kits. Its diagnostic services include examinations for breast cancer and colorectal cancer, while its biosensor solutions target point of care testing (POCT). Additionally, LabGenomics sells healthy food as part of its product portfolio. The primary buyers of LabGenomics' services are healthcare institutions requiring diagnostic support, including hospitals and clinics. The company's molecular diagnostic services and cancer examinations are particularly sought after by medical facilities focused on specialized testing. Healthcare providers also purchase its biosensor solutions for immediate testing at the point of care. LabGenomics' product segments include IVD services, IVD products like DNA chips and PCR kits, cancer examination services, and healthy food. The company's molecular diagnostic services and cancer testing are key revenue drivers, while its biosensor for POCT and healthy food offerings serve complementary market segments. Labgenomics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Labgenomics Co stock

Net Change in Cash of Labgenomics Co is -17.75 B KRW in 2025.

Net Change in Cash of Labgenomics Co changed from -17.81 B KRW to -17.75 B KRW, representing a -0.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash Labgenomics Co since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's Labgenomics Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Labgenomics Co

All Key Metrics — Labgenomics Co